PURA Develops M&A Strategy To Capitalize On Cannabis Potential To Transform Trillion Dollar Beverage Industry
May 23 2019 - 9:47AM
InvestorsHub NewsWire
PURA Develops M&A Strategy To Capitalize On
Cannabis Potential To Transform Trillion Dollar Beverage
Industry
DALLAS, TX
-- May 23, 2019 -- InvestorsHub NewsWire -- Puration, Inc.
(USOTC:
PURA) (“PURA”) today announced a management update scheduled
one week from today to be published on the company’s website on May
30th, 2019. The update will include highlights on
the company’s recently published 2019 Q1 financial report and the
company’s corresponding $4 million 2019 revenue target and 300%
revenue growth goal for 2019. As CBD infused beverages
continues to rise in market prominence as the potential leading
growth performer in the overall cannabis sector, the management
presentation will include an overview of PURA’s developing merger
and acquisition strategy (M&A) to capitalize on the potential
of cannabis extracts infused into beverages to transform the global
trillion dollar beverage
industry.
Forbes Feature Excerpt From “How The Cannabis Industry Is
Revolutionizing The Beverage Sector” – See Complete Article
Here Published May 22nd,
2019
The first
phase of the cannabis industry focused on medical and adult uses of
cannabis. The major players that emerged in North America, Canopy
Growth, Tilray, Aurora, etc., as well as the smaller American
state-based producers, all focused on growing cannabis. The initial
result, especially in the US where interstate transport of
marijuana is still illegal, has been soaring production far
exceeding demand.
According to
Christopher Fenn, co-founder of Wildhorse Capital Partners, a
cannabis market-focused merchant bank in Calgary
Alberta:
“The
expected growth of the CBD infused beverages and foods will
transform the cannabis industry; taking it in a very different
direction than its initial trajectory. In the process, ushering in
a second, even greater, growth phase and an entirely new group of
beverage and food industry
startups.”
The company
posted its 2019 Q1 financial report earlier this week demonstrating
over a $1 million base annual revenue run rate. The company
also has a new $1.5 million order to produce private labeled CBD
water which is not yet reflected in the company’s financial
statement. Demand for the company’s cornerstone beverage
product, EVERx CBD Sports Water, has strained the company’s current
production capacity, but a second production facility is
anticipated to be online by the end of June. With expanded
production, management may consider revising its 2019 $4 million
revenue target upwards later this year. In addition to the $3
million in CBD beverage sales anticipated this year at the current
production capacity, management is targeting an additional $1
million in sales from new cannabis beverage sales the company is
currently in the process of
launching.
The
presentation next week will include an update on the impending
dividend Nouveau (USOTC:
NOUV) to PURA shareholders. The presentation will also
include highlights on PURA’s partnership with Kali-Extracts (aka
Kali, Inc.) (USOTC:
KALY) (“KALY”). KALY owns and operates a U.S. Patented
Cannabis Extraction Process. PURA has the sole license of the
U.S. Patented Cannabis Extraction Process for the beverage
industry.
PURA
Shareholder Dividend
PURA
management has recently updated its approach with NOUV to deliver
on the dividend of NOUV stock to PURA shareholders in conjunction
with the 2018 Q4 spinoff of PURA’s cannabis cultivation operation
to NOUV. A new website facilitating the acceleration of the
dividend issuance process is to be launched imminently. In
conjunction with the launch, PURA and NOUV management will detail
the role of the website and further details with the updated
dividend issuance strategy.
For more
information on Puration, visit http://www.purationinc.com
Disclaimer/Safe Harbor:
This news
release contains forward-looking statements within the meaning of
the Securities Litigation Reform Act. The statements reflect the
Company's current views with respect to future events that involve
risks and uncertainties. Among others, these risks include the
expectation that any of the companies mentioned herein will achieve
significant sales, the failure to meet schedule or performance
requirements of the companies' contracts, the companies' liquidity
position, the companies' ability to obtain new contracts, the
emergence of competitors with greater financial resources and the
impact of competitive pricing. In the light of these uncertainties,
the forward-looking events referred to in this release might not
occur. These statements have not been evaluated by the Food and
Drug Administration. These products are not intended to diagnose,
treat, cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800)
861-1350
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Sep 2023 to Sep 2024